Why does controlling wall shear stress matter for validating endothelial targets in hematologic disease?

Controlling wall shear stress replicates the hemodynamic forces present in post-capillary venules, where sickle cell adhesion and occlusion initiate. This enables mechanistic interrogation of endothelial targets under pathophysiologically relevant flow conditions. It ensures that observed inhibition of cell-cell interactions reflects true target engagement rather than static assay artifacts.

How does isolating the independent variable of endothelial activation state improve target validation in discovery pipelines?

By standardizing endothelial cell type, confluence, and pretreatment with inflammatory cytokines, the model isolates endothelial activation as a defined independent variable. This allows researchers to attribute changes in blood cell adhesion or aggregation specifically to endothelial-mediated pathways. It reduces noise from heterogeneous cell states, increasing confidence in target-specific effects during screening campaigns.

What quantitative dependent variable measurements enable assessment of microvascular occlusion risk in this model?

The system quantifies dependent variables such as occlusion frequency, blood cell transit time, and adhesion event duration under flow. These metrics provide continuous, objective readouts of microvascular flow impairment. They allow direct comparison of test compounds or genetic perturbations against baseline pathological conditions in a reproducible format.

Why are replication requirements across channels and experiments critical for cross-functional collaboration in hematologic drug discovery?

Replication ensures that observed effects on blood flow or adhesion are consistent across multiple microchannels and experimental runs, minimizing false positives. This consistency supports reliable data transfer between discovery biology, assay development, and preclinical teams. Standardized replication builds confidence in assay robustness, enabling go/no-go decisions based on concordant results.

What statistical analysis capabilities are required before implementing this microfluidic model in a lead identification workflow?

Implementation requires the ability to perform comparative statistical analysis (e.g., t-tests or ANOVA) on quantitative outputs like occlusion rates or velocity distributions across conditions. Researchers must define effect size thresholds and statistical power needs based on expected biological variability. Pre-implementation planning should include sample size justification and normalization strategies to account for inter-device variability in channel dimensions or coating efficiency.

Hematolojik Hastalıklarında Mikrovasküler Etkileşimleri Öğrenmenin Endothelialized Mikroakiskan

15.7K views

Cited by 52

11:08 min

June 22nd, 2012

10.3791/3958-v

June 22nd, 2012

15.7K views

David R. Myers^*¹^,²^,³^,⁴ , Yumiko Sakurai^*¹^,²^,³^,⁴ , Reginald Tran¹^,²^,³^,⁴ , Byungwook Ahn¹^,²^,³^,⁴ , Elaissa Trybus Hardy¹^,²^,³^,⁴ , Robert Mannino¹^,²^,³^,⁴ , Ashley Kita¹^,²^,³^,⁴ , Michelle Tsai¹^,²^,³^,⁴ , Wilbur A. Lam¹^,²^,³^,⁴

¹Department of Pediatrics, Emory University School of Medicine, ²Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, ³Aflac Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta , ⁴Winship Cancer Institute of Emory University

^* These authors contributed equally

Mikrovasküler ölçekli kanallar (<30 um) ile bir mikroakışkan cihazın bütün iç yüzeyi boyunca kültürün 3B, endotel hücre mono tabakasında için bir yöntem tarif edilmiştir. Bu In vitro Mikrovasküler modeli kan hücreleri, endotelyal hücreler ve kan hastalıkları çözünür faktörler arasında biofiziksel etkileşimlerin çalışma sağlar.